🔗 Share this article

The recently developed medications for gonorrhoea in many years are being hailed as a "significant breakthrough" in the fight against increasingly resistant strains of the infection, according to researchers.

An International Public Health Issue

Cases of gonorrhoea are increasing worldwide, with figures suggesting more than 82 million infections per year. Notably increased rates are observed in the African continent and nations within the WHO's Western Pacific region, which encompasses Mongolia and China to New Zealand. In England, cases have reached a all-time high, while figures across Europe in 2023 were three times higher compared to figures for 2014.

“The approval of novel therapies for gonorrhoea is an significant and necessary step in the context of growing infection rates, increasing antimicrobial resistance and the very limited therapeutic options currently available.”

Public health authorities are increasingly worried about the rise in drug-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance found that the effectiveness of key first-line drugs like ceftriaxone and cefixime jumped significantly between 2022 and 2024.

Recent Drugs Secure Approval

One new antibiotic, marketed under the name Nuzolvence, was approved by the American regulatory agency in December for combating gonorrhoea. This infection can lead to major issues, including infertility. Researchers anticipate that targeted use of this new drug will help delay the emergence of superbugs.

Another new antibiotic, originating from the drugmaker GlaxoSmithKline, was also approved in close succession. This treatment, which is employed against UTIs, was proven in research to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

Zoliflodacin was the result of a unique collaborative effort for antibiotic development. The charitable organization Global Antibiotic Research & Development Partnership worked alongside the pharmaceutical company its industry partner to see it through.

“This approval marks a major breakthrough in the treatment of highly resistant gonorrhoea, which previously has been staying ahead of our drug pipeline.”

Clinical Trial Data and Worldwide Availability

As per data detailed in a prominent scientific publication, the new drug eradicated more than 90% of uncomplicated infections. This establishes an similar efficacy with the typical regimen, which uses an injection and a pill. The trial involved hundreds of patients from several countries including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the rights to register and commercialise the drug in numerous developing nations.

Clinicians directly involved have voiced hope. The availability of a easy-to-administer therapy such as this is hailed as a "revolutionary step" for managing the epidemic. This is considered essential to alleviate the strain of the illness for patients and to halt the transmission of untreatable gonorrhoea worldwide.